Miami FL 肾癌（肾细胞癌）临床试验
8项针对 肾癌（肾细胞癌）的研究正在 Miami及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
招募中1 期
- Research Site, Miami
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
招募中1 期
- NEO-811 Florida Site, Miami
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #47, Miami
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
招募中1/2 期
- Local Institution - 0177, Miami
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
招募中1/2 期
- Sylvester Comprehensive Cancer Center - Miami, Miami
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
招募中2 期
- Miami Cancer Institute, Miami
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
招募中3 期
- Miami Cancer Institute, Miami
A Study of VET3-TGI in Patients With Solid Tumors
招募中1 期
- University of Miami, Miami
其他城市的 肾癌（肾细胞癌）试验
- Houston, TX35 项研究
- New York City, NY27 项研究
- Dallas, TX23 项研究
- Nashville, TN23 项研究
- St. Louis, MO23 项研究
- Los Angeles, CA20 项研究
- Boston, MA16 项研究
- Baldwin Park, CA16 项研究
- Pittsburgh, PA15 项研究
- Philadelphia, PA15 项研究
- Queens, NY15 项研究
- Jacksonville, FL14 项研究
Miami的其他研究
- 乳腺癌42 项研究
- 癌症（所有类型）36 项研究
- 非小细胞肺癌31 项研究
- 前列腺癌27 项研究
- 肥胖症27 项研究
- 急性髓系白血病24 项研究
- 转移性癌症23 项研究
- 超重23 项研究
- 卵巢癌23 项研究
- 溃疡性结肠炎21 项研究
- 多发性骨髓瘤21 项研究
- 阿尔茨海默病20 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。